ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Dietary Supplement: calcitriol
Drug: dexamethasone
Genetic: protein expression analysis
Other: laboratory biomarker analysis

First Posted Date: 2007-09-03

Last Posted Date: 2017-11-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00524589

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Phase 1

Terminated

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: sunitinib malate
Other: flow cytometry
Other: pharmacological study

First Posted Date: 2007-09-03

Last Posted Date: 2016-06-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00524186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: thalidomide

First Posted Date: 2007-09-03

Last Posted Date: 2017-02-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00523848

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vitamin D in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Dietary Supplement: cholecalciferol

First Posted Date: 2007-09-03

Last Posted Date: 2015-11-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 148

Registration Number: NCT00524680

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Not Applicable

Withdrawn

Conditions: Pancreatic Cancer

First Posted Date: 2007-09-03

Last Posted Date: 2013-02-01

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00524069

Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: erlotinib hydrochloride
Other: immunohistochemistry staining method
Radiation: radiation therapy

First Posted Date: 2007-09-03

Last Posted Date: 2016-04-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00524121

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

Not Applicable

Terminated

Conditions: Precancerous/Nonmalignant Condition

Interventions: Procedure: laser therapy
Drug: aminolevulinic acid

First Posted Date: 2007-09-03

Last Posted Date: 2017-06-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00524485

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Liver Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: sunitinib malate
Other: laboratory biomarker analysis
Procedure: hepatic artery embolization
Procedure: quality-of-life assessment

First Posted Date: 2007-09-03

Last Posted Date: 2017-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00524316

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2007-09-03

Last Posted Date: 2014-08-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00524459

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
Recurrent Salivary Gland Cancer

Interventions: Drug: HPPH
Drug: photodynamic therapy
Procedure: conventional surgery

First Posted Date: 2007-05-07

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00470496

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy